Results 121 to 130 of about 21,434 (231)

The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Statins, widely prescribed for cardiovascular prevention, have emerged as potential disease‐modifying agents in neurodegenerative disorders due to their pleiotropic effects on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation.
Luigi Maria Chiatto, Lucia Buccarello, Giuseppe Carota, Rocco Salvatore Calabrò, Carmela Rifici, Emanuela Esposito, Alessio Ardizzone, Giuseppe Caruso   +7 more
wiley   +1 more source

Polymorphic study of donepezil hydrobromide

, 2005
1231-1235Six polymorphs of donepezil hydrobromide 1, having unique physical properties have been identified and characterized by various thermal, spectroscopic and powder X-Ray diffraction techniques.
Chalamala, Subrahmanyeswara Rao, Kolla, Naveenkumar, Vurimidi, Himabindu, Vankawala, Pravinchandra J, Mathad, Vijayavitthal T, Sundaram, Venkataraman, Elati, Chandrashekar R, Gangula, Srinivas   +7 more
core  

Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones

, 2004
1 The effects of donepezil, one of the most common cholinesterase inhibitors used for treatment of Alzheimer's disease, were studied on nicotinic receptors (nAChRs)-mediated postsynaptic currents, in dopaminergic neurons of the substantia nigra pars ...
Nicola B. Mercuri, Giorgio Bernardi, DI ANGELANTONIO, SILVIA   +2 more
core   +1 more source

6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis

Phytotherapy Research, Volume 40, Issue 6, Page 3132-3149, June 2026.
Doxorubicin induces cardiac and skeletal muscle atrophy by upregulating E3 ubiquitin ligases, inhibiting myogenic regulatory factors, and activating necroptosis. Cardiac atrophy can further exacerbate cardiotoxicity. 6‐Shogaol negatively regulates these processes and attenuates doxorubicin‐induced cardiac and skeletal muscle atrophy.
Xipeng Sun, Yaxian Wang, Quanjun Yang, Bo Xin, Jinlu Huang, Cheng Guo   +5 more
wiley   +1 more source

Prevention of postoperative delirium with donepezil

, 2015
In einer randomisierten Doppelblindstudie wurde die Effektivität und Sicherheit der perioperativen Einnahme des Cholinesteraseinhibitors Donepezil zur Prävention des postoperativen Delirs getestet.
Lingg, Charlotte
core  

Restoring Septohippocampal Cholinergic Signaling Rescues Surgery‐Induced Neurogenesis and Memory Deficits in Aged Mice

Aging Cell, Volume 25, Issue 6, June 2026.
Surgery‐induced MS/vDB → DG cholinergic decline impairs hippocampal neurogenesis and memory in aged mice; galantamine‐mediated cholinergic potentiation or sustained chemogenetic activation rescues these deficits, highlighting therapeutic potential for POCD.
Lei Lei, Qingsheng Meng, Xiaoyu Hu, Jinjin Yang, Ni Du, Songxue Su, Kenji Hashimoto, Jing Cao, Jian‐jun Yang   +8 more
wiley   +1 more source

Biological and In Silico Evaluation of Novel Methoxyphenol–1,2,3‐Triazole Hybrids as Multifunctional Anti‐Alzheimer's and Anticancer Agents

Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.
Novel methoxyphenol‐1,2,3‐triazole hybrids were synthesized as multifunctional leads. Compound 5e exhibited potent PC3 cytotoxicity (IC50: 3.57 μM), while 5c showed superior AChE inhibition (IC50: 1.44 μM) and high selectivity (SI: 6.22). DFT and docking studies confirmed their dual‐targeting potential, providing a robust scaffold for Alzheimer's and ...
Sultan Onur, Mustafa Çeşme, Ferhan Tümer   +2 more
wiley   +1 more source

The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross‐Sectional Study

Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.
Total flavonoid intake was significantly inversely associated with neurodegenerative diseases risk. Participants in the highest quartile (Q4) of total flavonoid intake exhibited a 48% lower risk compared to those in the lowest quartile (Q1) (OR = 0.52, 95% CI: 0.31–0.90; p for trend = 0.016).
Chenzhong Zong, Yang Dong, Xue Yu, Yu He, Xiaoqing Zhang, Kuo Gao   +5 more
wiley   +1 more source

Donepezil in the treatment of agitation in Alzheimer's disease

, 2007
Background: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.
A. S. Burns (7589282), Juszczak, E, Clive G. Ballard, Knapp, M, Knapp, Martin, Howard, RJ, Wilcock, G, Brown, R.G.; id_orcid, Jacoby, R., R. G. Brown (7589276), Bentham, Peter, Robert J. Howard, R. J. Howard (7589264), Bullock, Roger A., Burns, AS, Wilcock, Gordon, Jones, R., Holmes, C, Ballard, Clive G., John T. O'Brien, Jacoby, Robin, Holmes, C., Clive Holmes, Roy W. Jones, Lindesay, J., Jones, RW, Wilcock, G., Brown, RG, Brown, R., C. Katona (6059216), Rodger M. (7589303), P. Bentham (7589273), Robin Jacoby, Howard, R., Tony Johnson, Peter Bentham, Michaela Rodger, E. Juszczak (7589267), O'Brien, John T., Roger Bullock, CALM-AD Trial Group (7589306), Toby Johnson (43283), Jones, R.W., Jones, R, James Lindesay (7582160), R. Jacoby (7589288), C. G. Ballard (7589270), Ballard, C., Bullock, Roger, Juszczak, Edmund, C. Holmes (7589285), DeCesar, J, M. Knapp (2534038), Edmund Juszczak, Johnson, T, Howard, Robert J., Brown, Richard G., Jacoby, R, R. W. Jones (7589297), James Lindesay, Johnson, T., Ballard, CG, Ashby, D, J. DeCesare (7589300), ?, ?, Gordon Wilcock, Bullock, R., Juszczak, E., Julia DeCesare, CALM-AD Trial Group, G. Wilcock (7589294), Jones, Roy W., Rodger, M., Holmes, Clive, Katona, C, Bullock, R, Lindesay, J, Cornelius Katona, Burns, A.S., Richard G. Brown, Johnson, Tony, Katona, C., DeCesare, J., Knapp, Martin R J., Knapp, M., Burns, A., Lindesay, James, O'Brien, J., Bentham, P., Katona, Cornelius, DeCesare, Julia, Lawlor, B, O'Brien, J.T., Burns, Alistair, Rodger, M, Alistair S. Burns, Rodger, Michaela, R. Bullock (7589279), O'Brien, JT, Findlay, D, Bentham, P, J. T. O Brien (7589291), Decesare, J, Martin Knapp   +103 more
core   +1 more source

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source